Ketamine for Depression in ICU Patients

(KID-ICU Trial)

This trial tests whether ketamine, a fast-acting antidepressant, can quickly relieve depression in ICU patients. Many ICU patients experience depression, which can slow recovery and affect overall health. Unlike regular antidepressants, ketamine acts quickly, but its safety and effectiveness in this setting remain unclear. Participants must have been in the ICU for at least six days and show moderate to severe signs of depression. The study compares ketamine to a placebo, a non-active treatment that looks the same, to determine its impact on mood and recovery. As a Phase 2 trial, this research measures ketamine's effectiveness in an initial, smaller group, offering a chance to contribute to important findings.

Past studies have shown that ketamine is well-tolerated at low doses for treating depression. Administered through an IV at a controlled, low dose, it helps reduce serious side effects. Reported side effects include mild dizziness, nausea, or a temporary increase in blood pressure, which are typically short-lived and manageable.

Researchers are excited about ketamine for treating depression in ICU patients because it offers a faster-acting alternative to traditional antidepressants like SSRIs or SNRIs, which often take weeks to show effects. Ketamine works differently by targeting the NMDA receptors in the brain, potentially providing rapid relief from depressive symptoms. Additionally, its administration as an intravenous infusion allows for precise control of dosage and immediate monitoring of patient response, which is crucial in a critical care setting.

Research shows that ketamine can quickly alleviate depression symptoms. In some studies, patients felt better immediately after treatment, with benefits lasting up to a month. A review of various trials found that intravenous ketamine significantly reduced depression symptoms, even in those with major depressive episodes. One study found that more than half of the participants experienced significant relief from severe depression after just a few treatments. In this trial, participants in the experimental arm will receive intravenous subanesthetic ketamine. Early reports from ICU settings suggest ketamine might improve mood and sleep, but further research is needed to confirm these findings in seriously ill patients.⁶⁷⁸⁹¹⁰